Lipoprotein-associated markers for cardiovascular disease

Details Lipoprotein-associated markers for cardiovascular disease Lipoprotein-associated markers for cardiovascular disease

2011-07-05

2011-07-05

Cook, Lisa (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007100, C436S501000, C436S518000

Reexamination Certificate

active

07972802

ABSTRACT:
The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop, or is suffering from, cardiovascular disease. The methods comprise detecting an amount of at least one biomarker in a biological sample, or HDL subfraction thereof, from the subject, and comparing the detected amount of the biomarker to a predetermined value, where a difference between the detected amount and the predetermined value is indicative of the presence or risk of cardiovascular disease in the subject. In some embodiments, the biomarker comprises at least one of ApoC-IV, Paraoxonase 1, C3, C4, ApoA-IV, ApoE, ApoL1, C4B1, Histone H2A, ApoC-II, ApoM, Vitronectin, Haptoglobin-related protein, and Clusterin, or combinations thereof.

REFERENCES:
patent: 4677057 (1987-06-01), Curtiss et al.
patent: 6107045 (2000-08-01), Koren et al.
patent: 6225047 (2001-05-01), Hutchens
patent: 6521226 (2003-02-01), Radtke
patent: 6677114 (2004-01-01), Schneider et al.
patent: 6869568 (2005-03-01), Fogelman et al.
patent: 2002/0098597 (2002-07-01), Koren et al.
patent: 2002/0164598 (2002-11-01), Muhlestein et al.
patent: 2002/0164662 (2002-11-01), Hazen et al.
patent: 2003/0150003 (2003-08-01), Rubin et al.
patent: 2004/0053321 (2004-03-01), Koren et al.
patent: 2004/0053367 (2004-03-01), Griffin et al.
patent: 2004/0096917 (2004-05-01), Ivey et al.
patent: 2004/0158879 (2004-08-01), Ruvkun et al.
patent: 2004/0197823 (2004-10-01), Najib et al.
patent: 2004/0198656 (2004-10-01), Najib et al.
patent: 2005/0003341 (2005-01-01), Polansky
patent: 2005/0079562 (2005-04-01), Thompson
patent: 2005/0142569 (2005-06-01), Guild et al.
patent: 2005/0181451 (2005-08-01), Bates
patent: 2005/0192755 (2005-09-01), Nagalla et al.
patent: 1186299 (2002-03-01), None
patent: 0767914 (2004-09-01), None
patent: WO 86/05493 (1986-09-01), None
patent: WO 87/02059 (1987-04-01), None
patent: WO 88/03175 (1988-05-01), None
patent: WO 96/00903 (1996-01-01), None
patent: WO 00/49043 (2000-08-01), None
patent: WO 02/23191 (2002-03-01), None
patent: WO 02/063005 (2002-08-01), None
patent: WO 03/023407 (2003-03-01), None
patent: WO 03/025150 (2003-03-01), None
patent: WO 03/083081 (2003-10-01), None
patent: WO 2004/043238 (2004-05-01), None
patent: WO 2004/044165 (2004-05-01), None
patent: WO 2005/011474 (2005-02-01), None
Qian et al., Proteomics, vol. 5, 2005, pp. 572-584.
Allan, C.M., and J.M. Taylor, “Expression of a Novel Human Apolipoprotein (apoC-IV) Causes Hypertriglyceridemia in Transgenic Mice,”J. Lipid Res. 37:1510-1518, 1996.
Artl, A., et al., “Role of Serum Amyloid A During Metabolism of Acute-Phase HDL by Macrophages,”Arterioscler. Thromb. Vasc. Biol. 20:763-772, 2000.
Ayub, A., et al., “Serum Paraoxonase After Myocardial Infarction,”Arterioscler. Thromb. Vasc. Biol. 19:330-335, 1999.
Bergmeier, C., et al., “Distribution Spectrum of Paraoxonase Activity in HDL Fractions,”Clin. Chem. 50(12):2309-2315, 2004.
Bergt, C., et al., “The Myeloperoxidase Product Hypochlorous Acid Oxides HDL in the Human Artery Wall and Impairs ABCA1-Dependent Cholesterol Transport,”PNAS 101(35):13032-13037, 2004.
Bu, X., et al., “Linkage Analysis of the Genetic Determinants of High Density Lipoprotein Concentrations and Composition: Evidence for Involvement of the Apolipoprotein A-II and Cholesteryl Ester Transfer Protein Loci,”Hum. Genet. 93:639-648, 1994.
Buring, J.E., “Decreased HDL2and HDL3Cholesterol, Apo A-I and Apo A-II, and Increased Risk of Myocardial Infarction,”Circulation 85:22-29, 1992.
Chait, A., et al., “Lipoprotein-Associated Inflammatory Proteins: Markers or Mediators of Cardiovascular Disease?”J. Lipid Res., 46:389-403, 2005.
Ezeh, B., et al., “Plasma Distribution of apoA-IV in Patients With Coronary Artery Disease and Healthy Controls,”J. Lipid Res. 44:1523-1529, 2003.
Getz, G.S., “Immune Function in Atherogenesis,”J. Lipid Res. 46:1-10, 2005.
Halkes, C.J.M., et al., “Postprandial Increase of Complement Component 3 in Normolipidemic Patients With Coronary Artery Disease—Effects of Expanded-Dose Simvastatin,”Arterioscler. Thromb. Vasc. Biol. 21:1526-1530, 2001.
Hasler-Rapacz, J., et al., “Elevated Concentrations of Plasma Lipids and Apolipoproteins B, C-III, and E Are Associated With the Progression of Coronary Artery Disease in Familial Hypercholesterolemic Swine,”Art., Thromb. and Vasc. Biol. 15:583-592, 1995.
Hatsukami, R.L.S., et al., “The Correlation of Paraoxonase (PON1) Enzyme Activities With Plasma Lipid and LipoProtein Levels Differs for Subjects With and Without Vascular Disease,”J. Lipid Res., Jul. 1, 2005.
Jarvik, G.P. et al., “Paraoxonase Activity, but Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease,”Arterioscler. Thromb. Vasc. Biol. 23:1465-1471, 2003.
Karlsson, H., et al., “Lipoproteomics II: Mapping of Proteins in High-Density Lipoprotein Using Two-Dimensional Gel Electrophoresis and Mass Spectometry,”Proteomics 5:1431-1445, 2005.
Klos, et al., “Genome-Wide Linkage Analysis Reveals Evidence of Multiple Regions That Influence Variation in Plasma Lipid and Apolipoprotein Levels Associated With Coronary Heart Disease,”Arteriosclerosis Thrombosis and Vascular Biology 21:971-978 (2001).
Kotite, L., et al., “Human apoC-IV: Isolation, Characterization, and Immunochemical Quantification in Plasma and Plasma Lipoproteins,”J. Lipid Res. 44:1387-1394, 2003.
Manzato, E. et al., “Levels and Physicochemical Properties of Lipoprotein Subclasses in Moderate Hypertriglyceridemia,”Clin. Chimica Acta 219:57-65 (1993).
Mendez, A.J., et al., “Protein Kinase C as a Mediator of High Density Lipoprotein Receptor-Dependent Efflux of Intracellular Cholesterol,”J. Biol. Chem. 266(16):10104-10111, 1991.
Muscari, A. et al., “Relationship Between Serum C3 Levels and Traditional Risk Factors for Myocardial Infarction,”Acta Cardiologica 53(6):345-354.
Olsen, J.V., and M. Mann, “Improved Peptide Identification in Proteomics by Two Consecutive Stages of Mass Spectrometric Fragmentation,”PNAS 101(37):13417-13422, 2004.
Onat, A., et al., “Cross-Sectional Study of Complement C3 as a Coronary Risk Factor Among Men and Women,”Clin. Sci. (Lond.) 108(2):129-135, 2005.
Resing, K.A., “Proteomics for Cell Protein Expression Profiling,”J. Investigative Dermatology, 0022-202X/03, xi-xii, 2003.
Sacks, F.M., et al., “VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial,”Circulation 102:1886-1892, 2000.
Sampietro, T., et al., “Up Regulation of C3, C4, and Soluble Intercellular Adhesion Molecule-1 Co-Expresses With High Sensitivity C Reactive Protein in Familial Hypoalphalipoproteinaemia: Further Evidence of Inflammatory Activiation,”Heart 90:1438-1442, 2004.
Vergès, B.L., et al., “Macrovascular Disease Is Associated With Increased Plasma Apolipoprotein A-IV Levels in NIDDM,”Diabetes 46:125-132, 1997.
Ansell, B.J., et al., “Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment,” Circulation 108:2751-2756, Dec. 2003.
Asztalos, B.F., and E.J. Schaefer, “High-Density Lipoprotein Subpopulations in Pathologic Conditions,” American Journal of Cardiology 91(7):12E-17E, 2003.
Barter, P.J., et al., “Antiinflammatory Properties of HDL,” Circulation Research 95:764-772, 2004.
Brinkmann, V., et al., “Neutrophil Extracellular Traps Kill Bacteria,” Science 303(5663):1532-1535, Mar. 2004, 9 pages of supplemental online materials.
Daugherty, A., et al., “Hypercholesterolemia Stimulates Angiotensin Peptide Synthesis and Contributes to Atheroscl

Affiliated with

Also associated with

Rating

Lipoprotein-associated markers for cardiovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipoprotein-associated markers for cardiovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoprotein-associated markers for cardiovascular disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2686728